SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

VeonGen Reports FDA Alignment on VG801 Phase 3 Study Design

VeonGen says it aligned with the FDA on the pivotal Phase 3 study design and CMC strategy for VG801, a treatment for Stargardt disease.

Related stories